457 related articles for article (PubMed ID: 38512763)
1. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
Benedé-Ubieto R; Cubero FJ; Nevzorova YA
Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
[TBL] [Abstract][Full Text] [Related]
2. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
3. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
[TBL] [Abstract][Full Text] [Related]
4. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
Gabbia D; De Martin S
Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
[TBL] [Abstract][Full Text] [Related]
6. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
7. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
9. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
Lu X; Yang R; Chen Y; Chen D
iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
[TBL] [Abstract][Full Text] [Related]
10. The role of the microbiome in liver disease.
Schöler D; Schnabl B
Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
[TBL] [Abstract][Full Text] [Related]
11. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
13. Apelin and the gut microbiome: Potential interaction in human MASLD.
Effenberger M; Grander C; Hausmann B; Enrich B; Pjevac P; Zoller H; Tilg H
Dig Liver Dis; 2024 Jun; 56(6):932-940. PubMed ID: 38087672
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
16. Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance.
Choi KJ; Yoon MY; Kim JE; Yoon SS
Sci Rep; 2023 Sep; 13(1):14668. PubMed ID: 37674003
[TBL] [Abstract][Full Text] [Related]
17. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
Aggeletopoulou I; Tsounis EP; Triantos C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation in NAFLD Treatment.
Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
[No Abstract] [Full Text] [Related]
20. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
